Apalutamide (Erleada™) 60 mg or 240 mg tablets Clinical Trials
2 recruitingDrug
Phase 11
Showing 1–2 of 2 trials
Recruiting
Phase 1
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer
ORIC Pharmaceuticals250 enrolled27 locationsNCT05413421
Recruiting
PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
Prostate CancerMetastatic CancerCastrate Sensitive Prostate Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS152 enrolled1 locationNCT06652607